MannKind Corporation today announced that it has entered into a purchase agreement with The Mann Group LLC, an entity controlled by MannKind's chief executive officer and principal stockholder, Alfred E. Mann, for the sale of shares of its common stock to The Mann Group.

Arena Pharmaceuticals, Inc. announced today that it has agreed to sell 9,953,250 shares of its common stock, at a price of $1.65775 per share, and approximately 9,953 shares of its Series D Convertible Preferred Stock, at a price of $1,657.75 per share, in a registered direct public offering to entities ...

VirtualScopics, Inc., a leading provider of image-based solutions to the pharmaceutical, biotechnology and medical device industries, announced today that on January 4, 2012 it received a notice from the NASDAQ Stock Market indicating that the Company's minimum bid price has fallen below $1.00 for 30 consecutive business days.

Alexion Pharmaceuticals, Inc. and Enobia Pharma Corp. today announced that the companies have signed a definitive agreement under which Alexion will acquire 100% of the capital stock of Enobia.

Novelos Therapeutics, Inc., a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, today announced the pricing of an underwritten public offering of 9,840,000 units at $0.60 per unit for gross proceeds of $5,904,000.

Cadence Pharmaceuticals, Inc. today announced its intention to offer and sell $75 million worth of shares of its common stock in an underwritten public offering.

Cubist Pharmaceuticals, Inc. today announced the commencement of its tender offer for all outstanding shares of the common stock of Adolor Corporation for $4.25 per share in cash, plus one nontransferable Contingent Payment Right entitling the holder to receive additional cash payments of up to $4.50 for each share tendered ...

Thoratec Corporation, a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, announced today that its Board of Directors has authorized the repurchase of an additional $50 million of the company's shares of common stock over the next year.

Chemed Corporation announced today that the Board of Directors has formally authorized an additional $100 million for stock repurchase under Chemed's existing share repurchase program. These share repurchases will be funded through a combination of cash generated from operations as well as utilization of its revolving credit facility.

Health Care REIT, Inc. today announced the pricing of its underwritten public offering of 11,000,000 shares of common stock at $50.00 per share.

Idera Pharmaceuticals, Inc. today announced it has raised $9.5 million in a convertible preferred stock offering.

NanoViricides, Inc. announced that its President, Dr. Anil Diwan, has completed the programmed sale of the NanoViricides stock that he had obtained as a founder.